The potential off-target activities of pharmacological MAP4K inhibition and toxicities observed with first-generation MAP4K4 inhibitors argue for the specific repression of certain but not all effector functions of MAP4K4 to halt its oncogenic or tumor-promoting functions. Here, MAP4K4 is linked to neoplasm.